See more : The Goodyear Tire & Rubber Company (GTR.DE) Income Statement Analysis – Financial Results
Complete financial analysis of PROCEPT BioRobotics Corporation (PRCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PROCEPT BioRobotics Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Getaround, Inc. (GETR) Income Statement Analysis – Financial Results
- ADDvise Group AB (publ) (ADDV-A.ST) Income Statement Analysis – Financial Results
- China Avionics Systems Co.,Ltd. (600372.SS) Income Statement Analysis – Financial Results
- Chr. Hansen Holding A/S (CHYHY) Income Statement Analysis – Financial Results
- Pacific Online Limited (0543.HK) Income Statement Analysis – Financial Results
PROCEPT BioRobotics Corporation (PRCT)
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 136.19M | 75.01M | 34.47M | 7.72M | 6.17M |
| Cost of Revenue | 65.14M | 37.93M | 18.61M | 8.97M | 8.05M |
| Gross Profit | 71.05M | 37.09M | 15.87M | -1.26M | -1.89M |
| Gross Profit Ratio | 52.17% | 49.44% | 46.02% | -16.26% | -30.56% |
| Research & Development | 48.45M | 28.98M | 18.99M | 16.28M | 13.15M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.77M | 88.83M | 51.04M | 30.27M | 28.52M |
| Other Expenses | 0.00 | -203.00K | -154.00K | -25.00K | -46.00K |
| Operating Expenses | 180.22M | 117.81M | 70.03M | 46.55M | 41.67M |
| Cost & Expenses | 245.36M | 155.74M | 88.64M | 55.52M | 49.72M |
| Interest Income | 7.55M | 2.01M | 121.00K | 184.00K | 1.15M |
| Interest Expense | 4.00M | 5.18M | 5.81M | 5.26M | 724.00K |
| Depreciation & Amortization | 3.81M | 4.32M | 2.98M | 2.70M | 1.49M |
| EBITDA | -98.10M | -77.65M | -51.06M | -45.06M | -39.76M |
| EBITDA Ratio | -72.03% | -104.93% | -156.77% | -580.32% | -663.85% |
| Operating Income | -109.17M | -80.72M | -54.16M | -47.80M | -43.55M |
| Operating Income Ratio | -80.16% | -107.61% | -157.12% | -619.44% | -705.95% |
| Total Other Income/Expenses | 3.27M | -6.43M | -5.69M | -5.22M | 1.58M |
| Income Before Tax | -105.90M | -87.15M | -59.85M | -53.02M | -41.98M |
| Income Before Tax Ratio | -77.76% | -116.18% | -173.62% | -687.04% | -680.42% |
| Income Tax Expense | 0.00 | 6.43M | 2.53M | 5.24M | 678.00K |
| Net Income | -105.90M | -93.58M | -62.38M | -58.26M | -42.65M |
| Net Income Ratio | -77.76% | -124.76% | -180.96% | -754.89% | -691.41% |
| EPS | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| EPS Diluted | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| Weighted Avg Shares Out | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
| Weighted Avg Shares Out (Dil) | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
Procept BioRobotics resumed with an Overweight at Wells Fargo
Wells Fargo resumed coverage of Procept BioRobotics with an Overweight rating and $112 price target. The firm believes aquablation remains early stages in its adoption, which will be further supported by a new product cycle, the analyst tells investors in...
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the...
Procept BioRobotics: Continued Growth Runway Ahead
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and operating leverage.
Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice
Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an...
All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an...
Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential
PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings.
PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters -...
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports